Canaccord Genuity Starts Harpoon Therapeutics (HARP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500, Dow futures muted after big bank earnings, chip slide weighs
- Oil prices ease as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Sysco calls on Teamsters to end LA strike after economic deal reached
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Wedbush Starts Harpoon Therapeutics (HARP) at Outperform
March 5, 2019 6:45 AM ESTWedbush analyst Robert Driscoll initiates coverage on Harpoon Therapeutics (NASDAQ: HARP) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.
Shares of Harpoon Therapeutics closed at $17.01 yesterday.
... More


